Navigation Links
The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference
Date:2/10/2009

The 2009 Personalized Medicine Conference is bringing together the wide variety of stakeholders in both the public and private sector to examine both the opportunities and challenges facing those involved in the development and realization of personalized medicine.

Baltimore, MD (PRWEB) February 10, 2009 -- Arrowhead's 2009 Personalized Medicine Conference is a full two day conference set to take place in Baltimore on April 23rd and 24th that will bring together leaders from industry, government and academia to discuss issues of central importance to the future of personalized medicine. Sessions will be held on a variety of topics integral to the development of personalized medicine, including, but not limited to:

- pharmacogenomics
- biomarkers
- molecular diagnostics
- pharmacogenetics

Sessions will not only cover the various scientific and clinical developments in this space, but also a plethora of other issues that will need to be resolved in order to ensure success in this field, including:

- future regulatory models for personalized medicine
- social, ethical and legal concerns
- economic issues (insurance coverage, reimbursement, etc.)

Patrick Terry, the Co-Founder of Genomic Health and the Founder of the Personalized Medicine Coalition will share with attendees how innovative diagnostic companies are securing value-based rather than cost-based payment and will discuss how these innovators are building compelling clinical and economic evidence to support coverage and value-based payment from payers.

Attendees will also hear from Robert L. Becker, Jr, MD, Ph.D, the Chief Medical Officer of the FDA's Office of In Vitro Diagnostic Device Evaluation and Safety on the role of laboratory tests in personalized medicine and from Asif Dhar, MD, MBA, a Senior Fellow at the Deloitte Center for Health Solutions on the issue of ROI in targeted therapies. Specifically, Dr. Dhar will discuss the barriers facing developers of personalized medicine as well as the benefits of adopting personalized medicine.

Twenty five other speakers will be on hand to discuss the following issues:

- value creation in personalized medicine
- financial transparency in personalized medicine
- private insurance and Medicare coverage of personalized medicine
- the payors' perspective on personalized medicine
- the role of biomarkers and molecular diagnostics in the future of medicine
- how personalized medicine is faring in clinical trials
- perspectives on how clinicians will use personalized therapies in the future
- the role of health information technology and informatics in personalized medicine
- legal, regulatory and ethical concerns facing developers of personalized medicine
- personalized medicine business models and market analysis

See Agenda

Other key speakers:

Michael Amos, Ph.D., Scientific Advisor, Chemical Science & Technology Laboratory, National Institute of Standards & Technology Measurement, ex-officio member, Secretary's Advisory Committee on Genetics Health and Society (SACGHS), Department of Health and Human Services
Keith Batchelder, MD, Chief Executive Officer and Founder, Genomic Healthcare Strategies
Colin Brenan, Ph.D., Chief Technology Officer, VP Business Development, Co-Founder, BioTrove, Inc.
Teresa DeLuca, MD, Vice President Dept of Personalized Medicine, Medco
Professor Herbert A. Fritsche Jr., Ph.D., Professor & Chief of Clinical Chemistry, University of Texas M. D. Anderson Cancer Center
David Lester, Executive Vice President, Corporate Development, Gene Express Inc.
Thomas Metcalfe, Ph.D., Head, Personalized Healthcare Portfolio, F. Hoffmann-La Roche Ltd.
Bruce Quinn, MD, Ph.D., Senior Health Policy Specialist, Foley and Hoag
Rebekah Rasooly, Program Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH)
Wayne Roe, Director, Celera Diagnostics, Director, In-Cube Ventures
Mollie Roth, Esq., Corporate Counsel, VP Business Development, Diaceutics
Surya Singh, M.D., Chief Medical Officer and Vice President of Clinical Development, Proventys, Inc.
Grail Sipes, Partner, Covington & Burling, Food and Drug Practice and Life Sciences Industry Group

For more information about this conference, please visit http://www.arrowheadpublishers.com or call 1-312-244-3703.

###

Read the full story at http://www.prweb.com/releases/personalizedmedicine/pharmacogenomics/prweb2002114.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Stallergenes Inaugurates the Biggest Pharmaceutical Allergen Production Unit in the World
2. Eyeforpharmas Marketing Summit is shaping up to be the biggest event of its kind ever
3. Panacea Pharmaceuticals Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazines Ten Biggest Medical Breakthroughs of 2007
4. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
5. Neogen Names New Senior Science Officer; Added to S&P Index
6. Nexsun Corp Names Industry Executive David Pyrce as Chief Executive Officer
7. NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations
8. Cequent Names Ted Hibben Chief Business Officer
9. Clarus Ventures Names Two New Partners
10. Xceleron Names Michael Butler as President & CEO
11. Genome Technology Names 2008 Tomorrows PIs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) ... company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar Ataxia ... , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is estimated ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... identity. The new Media Cybernetics corporate branding reflects a results-driven revitalization for a ... image analysis. The re-branding components include a crisp, refreshed logo and a new ...
(Date:5/23/2016)... OXFORD, England , May 23, 2016 ... Wednesday, May 25 th at 10:15 a.m. ET before ... about the role genetically engineered mosquitos can play in controlling ... known carrier of the Zika virus.      (Logo: ... genetically engineered male mosquito with a self-limiting gene. Trials in ...
(Date:5/22/2016)... ... 22, 2016 , ... Doctors in Rome say micronutrients found in certain foods ... Surviving Mesothelioma has just posted an article on the new research. Click here ... Clinical Sciences and Translational Medicine evaluated more than 150 studies on polyphenols in cancer ...
Breaking Biology Technology:
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):